Riskpilot← Back to searchSign inGet full accessAtlas Therapeutics AB
ABActiveOrg 5568152424LundResearch and experimental development on natural sciences and engineering · NACE 7210Est. 20100 employees
Revenue 2024
SEK 0
EBITDA margin
—
0% vs 2023
Equity ratio
36.2%
Financial strength
Net profit 2024
SEK -4K
0% vs 2023
| Revenue | SEK 0 | — |
| EBITDA | SEK -4K | +0% |
| Net profit | SEK -4K | +0% |
| Total assets | SEK 687K | -1% |
| Equity | SEK 249K | -2% |
| Employees | 0 | — |
Legal name
Atlas Therapeutics AB
Org number
5568152424
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
23 juli 2010
Share capital
SEK 50 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas i förening av ledamöterna
Company purpose
Föremålet för bolagets verksamhet skall i första hand vara att bedriva forskning, utveckling och produktion av antikroppar och andra typer av bindarmolekyler för kommersialisering inom området antikroppsbaserad terapi och därmed förenlig verksamhet.
Address
Lund
Email
info@alligatorbioscience.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Staff expenses | — | — | — | — | — |
| EBITDA | −1 | −5 | −8 | −4 | −4 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 |
| EBIT | −1 | −5 | −8 | −4 | −4 |
| Net financials | 439 | — | — | — | — |
| Profit before tax | 0 | −5 | −8 | −4 | −4 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | 0 | −5 | −8 | −4 | −4 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 709 | 704 | 696 | 692 | 687 |
| Equity | 271 | 266 | 258 | 254 | 249 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 438 | 438 | 438 | 438 | 438 |
| Total debt | 438 | 438 | 438 | 438 | 438 |
EBITDA margin
-400000.0%
This company
15.8%
Market median
-2531746% vs market
20202024
Equity ratio
36.2%
This company
38.2%
Market median
+5% vs market
20202024
Return on equity
-1.6%
This company
18.4%
Market median
-109% vs market
20202024
Net profit margin
-400000.0%
This company
8.1%
Market median
-4938372% vs market
20202024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20202024
Debt / equity
1.76×
This company
0.62×
Market median
-184% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Former (3) | ||
TJ Chief Auditor | Chief Auditor | 2020 – 2022 |
OC Chief Auditor | Chief Auditor | 2022 – 2022 |
AO Chief Auditor | Chief Auditor | 2022 – 2025 |
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Deputy Board Member | 2025 | |
| Chairman | 2022 | |
| Board of Directors | 2025 | |
| Former (4) | ||
| Board of Directors | 2020 – 2025 | |
| Deputy Board Member | 2022 – 2025 | |
| Chairman | 2021 – 2022 | |
| Deputy Board Member | 2020 – 2022 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 0001 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Alligator Bioscience AB
Atlas Therapeutics AB Board members of Atlas Therapeutics AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Tomas Johan Thuresson | Chief Auditor | 0 companies |
| Ola Christopher Carelius Larsmon | Chief Auditor | 0 companies |
| Anders Ola Bjärehäll | Chief Auditor | 0 companies |
| Eva Marie Gabrielle Svensson | Board of Directors | 0 companies |
| Laura Ila von Schantz | Deputy Board Member | 0 companies |
| Greta Katarina Höög | Deputy Board Member | 0 companies |
| Tora Malin Elisabeth Carlsson | Chairman | 0 companies |
| Søren Bregenholt Frederiksen | Chairman | 0 companies |
| Carl Johan Giléus | Board of Directors | 0 companies |
| Tina Anna Furebring | Deputy Board Member | 0 companies |